Dana-Farber Cancer Institute Faculty Among World’s Most Highly Cited Researchers for 2024
Dana-Farber Cancer Institute announced that 42 of its researchers have been named to the Highly Cited Researchers list of 2024.
Related Articles
Amivantamab/Lazertinib Combo Approaches EU Approval in EGFR+ Advanced NSCLC
The EMA’s CHMP has issued a positive opinion regarding the use of amivantamab plus lazertinib in select patients with EGFR+ non–small cell lung cancer.
Versamune HPV Could Bolster Long-Term Efficacy With Pembrolizumab in HPV16-Driven HNSCC
Experts discuss the ongoing investigation of Versamune HPV plus pembrolizumab and its potential effect on outcomes in first-line HPV16-driven HNSCC.
The Use of AI in Clinical Practice
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Introduction and Objectives to Advances in Targeted Therapy for Small Cell Lung Cancer
Ticiana Leal, MD, discusses how recently approved targeted therapies for small cell lung cancer (SCLC) significantly enhance survival outcomes and reshape treatment strategies for both…
2024 Updates in GI Cancer Feature FLOT Combinations, Restricted FDA Approvals by PD-L1 Expression, and More
Yelena Y. Janjigian, MD, highlights key takeaways and data from 2024 in the gastric and GEJ cancer field.
Pelotonia Raises $26.2 Million for Innovative Cancer Research in 2024
Pelotonia announced today an annual fundraising total of $26,200,095 in 2024, bringing all-time funds raised to $309,861,962 for innovative cancer research at
Beneath the Surface: Neoantigens beyond Chromosomal DNA Mutations
Summary:. The conventional wisdom is that the overwhelming majority of neoantigens arise from chromosomal DNA mutations; however, recent studies show that posttranscriptional and posttranslational events…
Lipsky Discusses Second-Generation BTK Inhibitors in Relapsed/Refractory CLL
During a Case-Based Roundtable® event, Andrew H. Lipsky, MD, moderated a discussion on the efficacy and safety of newer BTK inhibitors used to treat patients with…